These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32435228)

  • 1. A Retrospective Interventional Cohort Study to Assess the Safety and Efficacy of Sandostatin LAR for Treatment of Recurrent and/or Refractory Meningiomas.
    Hrachova M; Nguyen ENT; Fu BD; Dandekar MJ; Kong XT; Cadena G; Hsu FPK; Billimek J; Taylor TH; Bota DA
    Front Neurol; 2020; 11():373. PubMed ID: 32435228
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
    Norden AD; Ligon KL; Hammond SN; Muzikansky A; Reardon DA; Kaley TJ; Batchelor TT; Plotkin SR; Raizer JJ; Wong ET; Drappatz J; Lesser GJ; Haidar S; Beroukhim R; Lee EQ; Doherty L; Lafrankie D; Gaffey SC; Gerard M; Smith KH; McCluskey C; Phuphanich S; Wen PY
    Neurology; 2015 Jan; 84(3):280-6. PubMed ID: 25527270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of unresectable skull base meningiomas with somatostatin analogs.
    Schulz C; Mathieu R; Kunz U; Mauer UM
    Neurosurg Focus; 2011 May; 30(5):E11. PubMed ID: 21529167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue.
    Chamberlain MC; Glantz MJ; Fadul CE
    Neurology; 2007 Sep; 69(10):969-73. PubMed ID: 17785665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
    Graillon T; Sanson M; Campello C; Idbaih A; Peyre M; Peyrière H; Basset N; Autran D; Roche C; Kalamarides M; Roche PH; Fuentes S; Tabouret E; Barrie M; Cohen A; Honoré S; Boucekine M; Baumstarck K; Figarella-Branger D; Barlier A; Dufour H; Chinot OL
    Clin Cancer Res; 2020 Feb; 26(3):552-557. PubMed ID: 31969329
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy.
    Simó M; Argyriou AA; Macià M; Plans G; Majós C; Vidal N; Gil M; Bruna J
    Cancer Chemother Pharmacol; 2014 May; 73(5):919-23. PubMed ID: 24619496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review.
    Graillon T; Romano D; Defilles C; Saveanu A; Mohamed A; Figarella-Branger D; Roche PH; Fuentes S; Chinot O; Dufour H; Barlier A
    J Neurosurg; 2017 Sep; 127(3):660-669. PubMed ID: 27982767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
    Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
    J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between tumor location, size, and WHO grade in meningioma.
    Magill ST; Young JS; Chae R; Aghi MK; Theodosopoulos PV; McDermott MW
    Neurosurg Focus; 2018 Apr; 44(4):E4. PubMed ID: 29606048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic
    Brastianos PK; Twohy EL; Gerstner ER; Kaufmann TJ; Iafrate AJ; Lennerz J; Jeyapalan S; Piccioni DE; Monga V; Fadul CE; Schiff D; Taylor JW; Chowdhary SA; Bettegowda C; Ansstas G; De La Fuente M; Anderson MD; Shonka N; Damek D; Carrillo J; Kunschner-Ronan LJ; Chaudhary R; Jaeckle KA; Senecal FM; Kaley T; Morrison T; Thomas AA; Welch MR; Iwamoto F; Cachia D; Cohen AL; Vora S; Knopp M; Dunn IF; Kumthekar P; Sarkaria J; Geyer S; Carrero XW; Martinez-Lage M; Cahill DP; Brown PD; Giannini C; Santagata S; Barker FG; Galanis E
    J Clin Oncol; 2023 Jan; 41(3):618-628. PubMed ID: 36288512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
    Garland J; Buscombe JR; Bouvier C; Bouloux P; Chapman MH; Chow AC; Reynolds N; Caplin ME
    Aliment Pharmacol Ther; 2003 Feb; 17(3):437-44. PubMed ID: 12562458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anaplastic meningioma: octreotide therapy for a case of recurrent and progressive intracranial disease.
    Rammo R; Rock A; Transou A; Raghunathan A; Rock J
    J Neurosurg; 2016 Feb; 124(2):496-500. PubMed ID: 26274993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma.
    Johnson DR; Kimmel DW; Burch PA; Cascino TL; Giannini C; Wu W; Buckner JC
    Neuro Oncol; 2011 May; 13(5):530-5. PubMed ID: 21558077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake.
    Seystahl K; Stoecklein V; Schüller U; Rushing E; Nicolas G; Schäfer N; Ilhan H; Pangalu A; Weller M; Tonn JC; Sommerauer M; Albert NL
    Neuro Oncol; 2016 Nov; 18(11):1538-1547. PubMed ID: 27106404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the results of recurrent intracranial meningiomas treated with re-radiosurgery.
    Kim M; Lee DH; Kim Rn HJ; Cho YH; Kim JH; Kwon DH
    Clin Neurol Neurosurg; 2017 Feb; 153():93-101. PubMed ID: 28081463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgically resected skull base meningiomas demonstrate a divergent postoperative recurrence pattern compared with non-skull base meningiomas.
    Mansouri A; Klironomos G; Taslimi S; Kilian A; Gentili F; Khan OH; Aldape K; Zadeh G
    J Neurosurg; 2016 Aug; 125(2):431-40. PubMed ID: 26722844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
    McGovern SL; Aldape KD; Munsell MF; Mahajan A; DeMonte F; Woo SY
    J Neurosurg; 2010 May; 112(5):925-33. PubMed ID: 19799498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
    Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
    Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
    Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
    Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and technical comparison of Sandostatin® LAR® and other formulations of long-acting octreotide.
    Petersen H; Bizec JC; Schuetz H; Delporte ML
    BMC Res Notes; 2011 Sep; 4():344. PubMed ID: 21906300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.